Molecules Brilliantly Illuminated with Ultra Short Burst of Light

Often, it takes little more than a glance to recognize that someone is sick. But illnesses whose effects are readily perceptible to the human eye are usually in an advanced stage. With the aid of laser light, Munich researchers hope to be able to detect and diagnose diseases in their early stages, when they are most amenable to therapeutic intervention. However, this requires a very sharp view – one that can peer into the world of molecules. Myriads of molecules react in highly specific ways to light of certain wavelengths in the mid-infrared region. By absorbing particular wavelengths, each type of molecule in a sample imprints a specific signature on the transmitted beam, which serves as a molecular fingerprint. With a source of broadband mid-infrared light one detects the fingerprints of many molecular structures at once – in a sample of blood or aspirated air, for example. If the sample contains marker molecules that are associated with specific disease states, these too will reveal their presence in the spectrum of the transmitted infrared light.

LAP physicists have now constructed such a light source, which covers the wavelengths between 1.6 and 10.2 microns. The laser system exhibits watt-level average output power, and is well focusable which results in a highly brilliant infrared light source. This feature enhances the ability to detect molecules present in extremely low concentrations. In addition, the laser can produce trains of femtosecond pulses [a femtosecond is a millionth of a billionth of a second (10-15sec)], which makes it possible to carry out time-resolved as well as low-noise and highly- precise measurements.

At present, infrared spectroscopy is often based on the use of incoherent light, which provides coverage of the whole mid-infrared region. However, the relatively low brilliance of the beam produced by incoherent sources markedly reduces the ability to detect very weak molecular fingerprints. Synchrotron radiation produced in particle accelerators can alternatively be used, but such facilities are in short supply and are extremely expensive. However, laser-based methods can generate even brighter beams than synchrotrons do. 

“Of course, there is still a long way to go until we can diagnose cancer at much early stage than at present. We need a better understanding of disease markers and we have to design an efficient way to quantify them, for example,” says Marcus Seidel, one of the researchers involved in the project. “But now having significantly improved light sources available, we can begin to tackle these issues.” Moreover, the new laser system will find applications in areas beyond the biosciences. After all, the precise observation of molecules and their transformations is at the core of both chemistry and physics too.